Grobman Megan, Krumme Stacy, Outi Hilton, Dodam John R, Reinero Carol R
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA
J Feline Med Surg. 2016 Feb;18(2):176-81. doi: 10.1177/1098612X15581405. Epub 2015 May 11.
Feline allergic asthma is a chronic inflammatory disorder of the lower airways that may manifest with acute, life-threatening clinical signs. Tachykinins released from sensory nerves and immune cells binding neurokinin (NK)-1, NK-2 and NK-3 receptors have been implicated in asthma pathogenesis. Maropitant, an NK-1 receptor antagonist, blocks neuroimmune pathways and may be a viable treatment option for cats in asthmatic crisis. Using an experimental chronic allergic feline asthma model, we hypothesized that a single dose of maropitant given immediately after allergen challenge would blunt clinical signs, airway hyperresponsiveness (AHR) and airway eosinophilia.
Cats (n = 7) induced to have an asthmatic phenotype using Bermuda grass allergen (BGA) were enrolled in a prospective, placebo-controlled crossover design study. Cats randomly received maropitant (2 mg/kg SC) or placebo (saline SC) immediately post-BGA challenge, followed 12 h later by pulmonary mechanics testing and measurement of airway eosinophils. After a 2 week washout, cats were crossed-over to the alternate treatment. Study endpoints included subjective clinical scoring systems post-BGA challenge, ventilator-acquired pulmonary mechanics to assess AHR after bronchoprovocation with methacholine and collection of bronchoalveolar lavage fluid to quantify airway eosinophilia. Data were analyzed using a Mann-Whitney rank sum test with P <0.05 considered significant.
A single injection of maropitant failed to diminish clinical composite score (P = 0.902), visual analogue scale scoring (P = 0.710), AHR (P = 0.456) or airway eosinophilia (P = 0.165) compared with placebo.
A single injection of maropitant given immediately post-allergen challenge was ineffective at blunting clinical signs, AHR and airway eosinophilia, and cannot be recommended as treatment for feline status asthmaticus.
猫过敏性哮喘是一种下呼吸道慢性炎症性疾病,可能表现出急性、危及生命的临床症状。感觉神经和免疫细胞释放的速激肽与神经激肽(NK)-1、NK-2和NK-3受体结合,与哮喘发病机制有关。马罗皮坦是一种NK-1受体拮抗剂,可阻断神经免疫途径,可能是治疗猫哮喘危象的一种可行选择。利用实验性慢性过敏性猫哮喘模型,我们假设在过敏原激发后立即给予单剂量马罗皮坦可减轻临床症状、气道高反应性(AHR)和气道嗜酸性粒细胞增多。
使用百慕大草过敏原(BGA)诱导出哮喘表型的猫(n = 7)被纳入一项前瞻性、安慰剂对照的交叉设计研究。猫在BGA激发后立即随机接受马罗皮坦(2 mg/kg皮下注射)或安慰剂(生理盐水皮下注射),12小时后进行肺力学测试并测量气道嗜酸性粒细胞。经过2周的洗脱期后,猫交叉接受另一种治疗。研究终点包括BGA激发后的主观临床评分系统、用乙酰甲胆碱进行支气管激发后评估AHR的呼吸机获得性肺力学以及收集支气管肺泡灌洗液以量化气道嗜酸性粒细胞增多。使用Mann-Whitney秩和检验分析数据,P <0.05被认为具有统计学意义。
与安慰剂相比,单次注射马罗皮坦未能降低临床综合评分(P = 0.902)、视觉模拟量表评分(P = 0.710)、AHR(P = 0.456)或气道嗜酸性粒细胞增多(P = 0.165)。
在过敏原激发后立即单次注射马罗皮坦在减轻临床症状、AHR和气道嗜酸性粒细胞增多方面无效,因此不能推荐用于治疗猫哮喘持续状态。